Clinical Trials Browser

Multiple Myeloma × selinexor × Clear all

NCT06169215 2026-03-18

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT07479979 2026-03-18

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT03589222 2026-02-27

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05530421 2026-02-23

SELVEDge

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

Multiple Myeloma

NCT05954780 2026-01-14

SEATTLE

Active not recruiting

Multiple Myeloma

NCT04640779 2026-01-06

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05675319 2026-01-05

AlloRelapseMM

Phase 3 Terminated

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Phase 3 Active not recruiting

Multiple Myeloma

NCT02199665 2025-11-03

SINE

Phase 1 Completed

Multiple Myeloma

NCT06822972 2025-09-02

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Phase 2 Recruiting

Multiple Myeloma

NCT05900882 2025-08-17

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Phase 2 Recruiting

Multiple Myeloma

NCT04717700 2025-03-18

SABLe

Phase 2 Active not recruiting

Multiple Myeloma

NCT03732703 2025-02-14

MyDRUG

Phase 1/2 Completed

Multiple Myeloma

NCT05597345 2025-02-10

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Phase 2 Recruiting

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT06452446 2025-02-10

Selinexor

Active not recruiting

Plasma cellSarcoma

Multiple Myeloma, Dendritic Cell Sarcoma, Interdigitating

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT04756401 2024-09-26

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 2 FDA

Multiple Myeloma, Recurrence

NCT05820763 2024-07-10

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Phase 2 Withdrawn

Multiple Myeloma, Neoplasm, Residual

NCT05422027 2024-06-17

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06212596 2024-01-19

MUKtwelve

Phase 2 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04877275 2023-12-06

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Phase 2 Unknown

Multiple Myeloma

NCT04519476 2023-10-31

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Phase 1 Unknown

Multiple Myeloma

NCT04843579 2023-10-25

ClaSPd

Phase 2 Terminated

4 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03944057 2023-06-15

MARCH

Phase 2 Completed

82 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Phase 1 Completed

286 enrolled 26 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT02389543 2023-01-26

SLAM

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT02628704 2023-01-26

SCORE

Phase 2 Withdrawn

Multiple Myeloma

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

28 enrolled 10 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05170789 2022-05-04

ESdRRMM

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT04891744 2021-05-18

Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Phase 1/2 Unknown

Multiple Myeloma

NCT02831686 2020-11-24

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

Phase 1 Completed

Multiple Myeloma

NCT03850704 2019-02-22

Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma

No longer available

Multiple Myeloma